Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy

American Journal of Physiology - Renal Physiology

Volumn 284, Issue 2 53-2, 2003, Pages

  Yang, Junwei ^a   Liu, Youhua ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

C met; Myofibroblast; Renal fibrosis; Ureteral obstruction; smooth muscle actin

Indexed keywords

ALPHA ACTIN; COLLAGEN TYPE 1; FIBRONECTIN; RECOMBINANT SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY TUBULE EPITHELIUM; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; URETER OBSTRUCTION; WESTERN BLOTTING;

EID: 0037302457     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00154.2002     Document Type: Article

References (45)

1. Azuma H, Takahara S, Matsumoto K, Ichimaru N, Wang JD, Moriyama T, Waaga AM, Kitamura M, Otsuki Y, Okuyama A, Katsuoka Y, Chandraker A, Sayegh MH, and Nakamura T. Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol 12: 1280-1292, 2001.
2. Border WA and Noble NA. Interaction of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 31: 181-188, 1998.
3. Border WA and Noble NA. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int 51: 1388-1396, 1997.
4. Burkart JM, Pereira BJ, and Parker TF III. Strategies for influencing outcomes in pre-ESRD and ESRD patients. J Am Soc Nephrol 9: S2-S3, 1998.
5. Chevalier RL. Molecular and cellular pathophysiology of obstructive nephropathy. Pediatr Nephrol 13: 612-619, 1999.
6. Chevalier RL, Goyal S, and Thornhill BA. EGF improves recovery following relief of unilateral ureteral obstruction in the neonatal rat. J Urol 162: 1532-1536, 1999.
7. Chevalier RL, Kim A, Thornhill BA, and Wolstenholme JT. Recovery following relief of unilateral ureteral obstruction in the neonatal rat. Kidney Int 55: 793-807, 1999.
8. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7: 2495-2508, 1996.
9. Essawy M, Soylemezoglu O, Muchaneta-Kubara EC, Shortland J, Brown CB, and el Nahas AM. Myofibroblasts and the progression of diabetic nephropathy. Nephrol Dial Transplant 12: 43-50, 1997.
10. Fan JM, Ng YY, Hill PA, Nikolic-Paterson DJ, Mu W, Atkins RC, and Lan HY. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 56: 1455-1467, 1999.
11. Fern RJ, Yesko CM, Thornhill BA, Kim HS, Smithies O, and Chevalier RL. Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest 103: 39-46, 1999.
12. Hay ED and Zuk A. Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am J Kidney Dis 26: 678-690, 1995.
13. Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, Border WA, Noble NA, Kaneda Y, Hori M, and Imai E. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 55: 465-475, 1999.
14. Isaka Y, Tsujie M, Ando Y, Nakamura H, Kaneda Y, Imai E, and Hori M. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 58: 1885-1892, 2000.
15. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, and Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350, 2002.
16. Kivirikko KI, Laitinen O, and Prockop DJ. Modifications of a specific assay for hydroxyproline in urine. Anal Biochem 19: 249-255, 1967.
17. Klahr S. Urinary tract obstruction. Semin Nephrol 21: 133-145, 2001.
18. Klahr S and Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int 57, Suppl 75: S7-S14, 2000.
19. Laping NJ, Olson BA, Ho T, Ziyadeh FN, and Albrightson CR. Hepatocyte growth factor: a regulator of extracellular matrix genes in mouse mesangial cells. Biochem Pharmacol 59: 847-853, 2000.
20. Liu Y. Hepatocyte growth factor and the kidney. Curr Opin Nephrol Hypertens 11: 23-30, 2002.
21. Liu Y, Rajur K, Tolbert E, and Dworkin LD. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 58: 2028- 2043, 2000.
22. Liu Y, Tolbert EM, Lin L, Thursby MA, Sun AM, Nakamura T, and Dworkin LD. Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Kidney Int 55: 442-453, 1999.
23. Liu Y, Tolbert EM, Sun AM, and Dworkin LD. In vivo and in vitro evidence for increased expression of HGF receptor in kidney of diabetic rat. Am J Physiol Renal Fluid Electrolyte Physiol 271: F1202-F1210, 1996.
24. Lohr JW, Lee TP, Farooqui M, and Mookerjee BK. Increased levels of serum hepatocyte growth factor in patients with end-stage renal disease. J Med 31: 131-141, 2000.
25. Massague J, Blain SW, and Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309, 2000.
26. Matsumoto K and Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 59: 2023-2038, 2001.
27. Mizuno S, Kurosawa T, Matsumoto K, Mizuno-Horikawa Y, Okamoto M, and Nakamura T. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 101: 1827-1834, 1998.
28. Mizuno S, Matsumoto K, Kurosawa T, Mizuno-Horikawa Y, and Nakamura T. Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice. Kidney Int 57: 937-948, 2000.
29. Mizuno S, Matsumoto K, and Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 59: 1304-1314, 2001.
30. Morrissey J, Hruska K, Guo G, Wang S, Chen Q, and Klahr S. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 13: S14-S21, 2002.
31. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, and Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60: 587-596, 2001.
32. Okada H, Danoff TM, Kalluri R, and Neilson EG. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol Renal Physiol 273: F563-F574, 1997.
33. Port FK, Fenton SSA, and Mazzuchi N. ESRD throughout the world: morbidity, mortality and quality of life. Kidney Int 57: S1-S2, 2000.
34. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, and West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol Cell Physiol 277: C1-C9, 1999.
35. Remuzzi G and Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998.
36. Roberts IS, Burrows C, Shanks JH, Venning M, and McWilliam LJ. Interstitial myofibroblasts: predictors of progression in membranous nephropathy. J Clin Pathol 50: 123-127, 1997.
37. Stahl PJ and Felsen D. Transforming growth factor-beta, basement membrane, and epithelial-mesenchymal transdifferentiation: implications for fibrosis in kidney disease. Am J Pathol 159: 1187-1192, 2001.
38. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, and Neilson EG. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 130: 393-405, 1995.
39. Sutaria PM, Ohebshalom M, McCaffrey TA, Vaughan ED Jr, and Felsen D. Transforming growth factor-beta receptor types I and II are expressed in renal tubules and are increased after chronic unilateral ureteral obstruction. Life Sci 62: 1965-1972, 1998.
40. Vargas GA, Hoeflich A, and Jehle PM. Hepatocyte growth factor in renal failure: promise and reality. Kidney Int 57: 1426- 1436, 2000.
41. Wang SN and Hirschberg R. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am J Physiol Renal Physiol 278: F554-F560, 2000.
42. Yang J, Dai C, and Liu Y. Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther 8: 1470-1479, 2001.
43. Yang J and Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 13: 96-107, 2002.
44. Yang J and Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 159: 1465-1475, 2001.
45. Zeisberg M, Bonner G, Maeshima Y, Colorado P, Muller GA, Strutz F, and Kalluri R. Renal fibrosis: Collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 159: 1313-1321, 2001.